Spinel Karas

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Chemotherapy Induced

Top Venues

Clinical pharmacology and therapeutics

JCO oncology practice

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Spinel Karas, Ron H J Mathijssen, Ron H N van Schaik, Alan Forrest, Timothy Wiltshire, Robert R Bies, Federico Innocenti
Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model. Clinical pharmacology and therapeutics 115 (5) (2024)
Spinel Karas, Ron H J Mathijssen, Ron H N van Schaik, Alan Forrest, Timothy Wiltshire, Robert R Bies, Federico Innocenti
Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model. Clinical pharmacology and therapeutics (2024)
Spinel Karas, Ron H J Mathijssen, Ron H N van Schaik, Alan Forrest, Timothy Wiltshire, Robert R Bies, Federico Innocenti
Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model. Clinical pharmacology and therapeutics 115 (5) (2024)
Spinel Karas, Federico Innocenti
All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide. JCO oncology practice (2021)
Spinel Karas, Amy S Etheridge, Deborah A Nickerson, Nancy J Cox, Karen L Mohlke, Erika Cecchin, Giuseppe Toffoli, Ron H J Mathijssen, Alan Forrest, Robert R Bies, Federico Innocenti
Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients. British journal of cancer (2021)